On November 6, 2019 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, reported an abstract has been accepted for an oral presentation highlighting the company’s lead autoimmune/inflammatory program ALPN-101 at the 61stAmerican Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, FL (Press release, Alpine Immune Sciences, NOV 6, 2019, View Source [SID1234550436]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will present on its upcoming Phase 1/2 BALANCE study of ALPN-101 in steroid-resistant or steroid-refractory acute Graft-versus-Host Disease (GvHD). ALPN-101 is a first-in-class, dual inhibitor of the CD28 and ICOS costimulatory pathways with strong preclinical and translational rationale in GvHD.
Last year, preclinical data on ALPN-101 was included in an oral presentation at the 60th ASH (Free ASH Whitepaper) Annual Meeting, highlighting the novel role ICOS ligand (ICOS-L) plays in acute GvHD and extending what is currently understood about the CD28/B7 protein family in disease pathogenesis. Since then, Alpine has been conducting a first-in-human, randomized, placebo-controlled single- and multiple-ascending dose Phase I study in adult healthy volunteers. "This year’s presentation will discuss the translational and therapeutic potential of ALPN-101 based on our learnings to date," indicated Stanford Peng, M.D. Ph.D., President and Head of Research and Development at Alpine.
61st ASH (Free ASH Whitepaper) Annual Meeting Oral Presentation
Title: An Open Label Study of ALPN-101, a First-in-Class Dual CD28/ICOS Antagonist, in Subjects with Steroid-Resistant or Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)
Presenter: Dr. Jan Hillson, Senior Vice President, Clinical Development, Alpine
Session Name: 802. Chemical Biology and Experimental Therapeutics: Novel Compounds and Mechanisms of Action (9:30 – 11:15 AM ET)
Oral Presentation Date and Time: Sunday, December 8, 2019: 11:00 AM ET
Location: OCCC, W414AB
About Graft Versus Host Disease (GvHD)
Graft versus host disease (GvHD) is the most common life-threatening complication of a hematopoietic cell transplant. It occurs when donor cells see recipient cells as different and attack them. Acute GvHD typically occurs within the early weeks and months after transplant, usually involving the skin, liver and gastrointestinal tract. Despite extensive studies of many different therapies in GvHD, corticosteroids remain its primary treatment.
About ALPN-101
ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD), and a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely connected to multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease and multiple sclerosis, ALPN-101 demonstrates efficacy superior to blockade of the CD28 and/or ICOS pathways alone.